Abstract

Objective: To determine whether pretreatment moxibustion prevents asthma by down-regulating the lung RhoA/ROCK pathway in rats with bronchial asthma and benignly mediating the lung inflammatory response. Methods: Twenty Sprague Dawley (SD) rats were randomly divided into normal control group (C), asthma model group (M), suspended moxibustion 40 min +asthma group (SM40), and suspended moxibustion 10 min +asthma group (SM10). Ovalbumin was used as a sensitizer. The two moxibustion groups completed moxibustion treatment lasted 40 min or 10 min respectively 30 min before modeling onset, and was repeated five times in each modeling cycle, for a total of 15 times. Samples were harvested on day 30. Results: Lung impairment was significant in the M group, whereas pretreatment with SM10 and SM40 dramatically attenuated the injury. After modeling, mRNA expression of RhoA and ROCK2 in the lung tissue was significantly higher than that in C group (both P < 0.001), resulting in significant increase in protein levels of IL-17A (P < 0.001). Significant decrease in RhoA and ROCK2 mRNA expression was seen in the SM10 (P<0.001, P<0.01) and SM40 (both P<0.001) groups compared to that with M rats. The differential trend in the SM40 group was more evident than that in the SM10 group. Regarding IL-10 or IL-17A protein concentration, an upregulation or down-regulation was observed in both SM10 (P<0.05, P < 0.01) and SM40 groups (both P < 0.001) compared to that with the M group. Conclusions: Moxibustion pretreatment significantly prevented pulmonary inflammation in asthmatic rats, potentially via inhibition of the RhoA/ROCK pathway. The efficacty of moxibustion appeared to be significantly associated with the duration of intervention with moxibustion.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call